Royalty Pharma (RPRX) EBIT (QoQ) (2019 - 2026)
Royalty Pharma (RPRX) EBIT (QoQ) (2019 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
| 10 |
Royalty Pharma |
23.13 Bn |
25.57 Bn |
- |
| Date | Value |
|---|
| Mar 31, 2026 |
44.97% |
| Dec 31, 2025 |
-9.08% |
| Sep 30, 2025 |
103.60% |
| Jun 30, 2025 |
-60.73% |
| Mar 31, 2025 |
47.76% |
| Dec 31, 2024 |
-50.82% |
| Sep 30, 2024 |
172.62% |
| Jun 30, 2024 |
465.48% |
| Mar 31, 2024 |
-112.04% |
| Dec 31, 2023 |
304.71% |
| Sep 30, 2023 |
-39.14% |
| Jun 30, 2023 |
-48.05% |
| Mar 31, 2023 |
199.24% |
| Dec 31, 2022 |
-351.11% |
| Sep 30, 2022 |
-49.12% |
| Jun 30, 2022 |
71.94% |
| Mar 31, 2022 |
43.22% |
| Dec 31, 2021 |
-49.38% |
| Sep 30, 2021 |
-59.32% |
| Jun 30, 2021 |
224.88% |
